| 1 |
Chan_2018 |
Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations |
Chan, Marion M.; Chen, Rensa; Fong, Dunne |
2018 |
2018-10-01 |
PMC |
N |
PMC7117025 |
29960048.0 |
10.1016/j.canlet.2018.06.034 |
3cjr1rol |
0.705244 |
|
Chen_2019 |
| 2 |
Goldenberg_2008 |
Strategies for the Identification of novel inhibitors of deubiquitinating enzymes |
Goldenberg, Seth J; McDermott, Jeffrey L; Butt, Tauseef R; Mattern, Michael R; Nicholson, Benjamin |
2008 |
2008-09-19 |
PMC |
N |
PMC3061546 |
18793145.0 |
10.1042/bst0360828 |
r1xxiy0v |
0.557480 |
|
|
| 3 |
Farshi_2015 |
Deubiquitinases (DUBs) and DUB inhibitors: a patent review |
Farshi, Pershang; Deshmukh, Rahul R.; Nwankwo, Joseph O.; Arkwright, Richard T.; Cvek, Boris; Liu, Jinbao; Dou, Q. Ping |
2015 |
2015-06-16 |
PMC |
N |
PMC4834700 |
26077642.0 |
10.1517/13543776.2015.1056737 |
vm8os5gn |
0.547068 |
|
|
| 4 |
Mattern_2012 |
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors |
Mattern, Michael R.; Wu, Jian; Nicholson, Benjamin |
2012 |
2012-11-30 |
PMC |
N |
PMC7127515 |
22610084.0 |
10.1016/j.bbamcr.2012.05.005 |
sgh6adb2 |
0.547008 |
|
Chen_2019 |
| 5 |
Veggiani_2019 |
Emerging drug development technologies targeting ubiquitination for cancer therapeutics |
Veggiani, Gianluca; Gerpe, María Carla Rosales; Sidhu, Sachdev S.; Zhang, Wei |
2019 |
2019-07-31 |
PMC |
N |
PMC7112620 |
30851297.0 |
10.1016/j.pharmthera.2019.03.003 |
r4on3lpr |
0.518061 |
|
Edelmann_2011, Chen_2019 |
| 6 |
Fan_H_2017 |
Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium |
Fan, Hanlu; Du, Xiaohong; Zhang, Jingyuan; Zheng, Han; Lu, Xiaohui; Wu, Qihui; Li, Haifeng; Wang, Han; Shi, Yi; Gao, George; Zhou, Zhuan; Tan, Dun-Xian; Li, Xiangdong |
2017 |
2017-01-24 |
COMM-USE |
N |
PMC5259750 |
28117364.0 |
10.1038/srep41226 |
k86hzbbx |
0.511299 |
|
Chen_2019 |
| 7 |
de_Graaf_2018 |
Armed oncolytic viruses: A kick-start for anti-tumor immunity |
de Graaf, J.F.; de Vor, L.; Fouchier, R.A.M.; van den Hoogen, B.G. |
2018 |
2018-06-30 |
PMC |
N |
PMC7108398 |
29576283.0 |
10.1016/j.cytogfr.2018.03.006 |
qbvqny97 |
0.501562 |
|
Kaufman_2015, Martínez_2008 |
| 8 |
Klein_2009 |
HIV Coreceptors and Their Roles in Leukocyte Trafficking During Neuroinflammatory Diseases |
Klein, Robyn S.; McCandless, Erin E. |
2009 |
2009-06-24 |
PMC |
N |
PMC7120588 |
|
10.1007/978-1-4419-0793-6_6 |
oa3x63xd |
0.481965 |
|
Zhu_X_2015 |
| 9 |
Russell_2007 |
Viruses as anticancer drugs |
Russell, Stephen J.; Peng, Kah-Whye |
2007 |
2007-07-01 |
PMC |
N |
PMC3125087 |
17573126.0 |
10.1016/j.tips.2007.05.005 |
pl6uf13v |
0.472332 |
Li_C_2019, Wisskirchen_2014, Dove_2004 |
Kaufman_2015 |
| 10 |
Edelmann_2011 |
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases |
Edelmann, Mariola J.; Nicholson, Benjamin; Kessler, Benedikt M. |
2011 |
2011-11-23 |
NONCOMM |
N |
PMC3219211 |
22088887.0 |
10.1017/s1462399411002031 |
o44dtozb |
0.470645 |
|
Chen_2019, Veggiani_2019 |
| 11 |
Wanve_2018 |
Therapeutic spectrum of interferon‐β in ischemic stroke |
Wanve, Madhuri; Kaur, Harpreet; Sarmah, Deepaneeta; Saraf, Jackson; Pravalika, Kanta; Vats, Kanchan; Kalia, Kiran; Borah, Anupom; Yavagal, Dileep R.; Dave, Kunjan R.; Bhattacharya, Pallab |
2018 |
2018-10-15 |
PMC |
N |
PMC7167007 |
30320448.0 |
10.1002/jnr.24333 |
rkb9z5t9 |
0.470645 |
|
|
| 12 |
Antonelli_2015 |
Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use |
Antonelli, Guido; Scagnolari, Carolina; Moschella, Federica; Proietti, Enrico |
2015 |
2015-04-30 |
PMC |
N |
PMC7108252 |
25578520.0 |
10.1016/j.cytogfr.2014.12.006 |
9b11c0od |
0.464892 |
|
Martínez_2008 |
| 13 |
Singh_2016 |
Deubiquitinases and cancer: A snapshot |
Singh, Nishant; Singh, Anuradha Bharara |
2016 |
2016-07-31 |
PMC |
N |
PMC7128910 |
27211605.0 |
10.1016/j.critrevonc.2016.04.018 |
crl8bxo1 |
0.436146 |
|
Goldenberg_2008 |
| 14 |
Bailly_2019 |
Cepharanthine: An update of its mode of action, pharmacological properties and medical applications |
Bailly, Christian |
2019 |
2019-09-30 |
PMC |
N |
PMC7126782 |
31132753.0 |
10.1016/j.phymed.2019.152956 |
2ajvf1vx |
0.435789 |
|
Chen_2019 |
| 15 |
Ding_2019 |
Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation |
Ding, Xianting; Krutzik, Peter O.; Ghaffari, Amir Ali; Zhaozhi, Yixiu; Miranda, Daniel; Cheng, Genhong; Ho, Chih-Ming; Nolan, Garry P.; Sanchez, David Jesse |
2019 |
2019-11-30 |
PMC |
N |
PMC7114107 |
31513822.0 |
10.1016/j.antiviral.2019.104598 |
9lkd4o3l |
0.394551 |
|
|
| 16 |
Zhou_2011 |
Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis |
Zhou, Zheng; Liao, Jun-Ming; Zhang, Peng; Fan, Jun-Bao; Chen, Jie; Liang, Yi |
2011 |
2011-11-01 |
PMC |
N |
PMC4875183 |
22180089.0 |
10.1007/s13238-011-1096-0 |
0gtkqn81 |
0.374749 |
|
|
| 17 |
Chen_2019 |
The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications |
Chen, Xi; Xu, Zhijie; Zeng, Shuangshuang; Wang, Xiang; Liu, Wanli; Qian, Long; Wei, Jie; Yang, Xue; Shen, Qiuying; Gong, Zhicheng; Yan, Yuanliang |
2019 |
2019-09-03 |
COMM-USE |
N |
PMC6733886 |
31552177.0 |
10.3389/fonc.2019.00852 |
can4cvkx |
0.334203 |
|
Bailly_2019 |
| 18 |
Kim_D_2019 |
Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells |
Kim, Dong Eon; Min, Jung Sun; Jang, Min Seong; Lee, Jun Young; Shin, Young Sup; Park, Chul Min; Song, Jong Hwan; Kim, Hyoung Rae; Kim, Seungtaek; Jin, Young-Hee; Kwon, Sunoh |
2019 |
2019-11-04 |
COMM-USE |
N |
PMC6921063 |
31690059.0 |
10.3390/biom9110696 |
5ts3kk10 |
0.327840 |
|
Wu_H_2016 |
| 19 |
Es-Saad_2012 |
Regulators of innate immunity as novel targets for panviral therapeutics |
Es-Saad, Salwa; Tremblay, Nicolas; Baril, Martin; Lamarre, Daniel |
2012 |
2012-10-31 |
PMC |
N |
PMC7102864 |
23017246.0 |
10.1016/j.coviro.2012.08.009 |
nf6ouaq3 |
0.318214 |
|
Martínez_2008 |
| 20 |
Keating_2011 |
Phosphorylation events during viral infections provide potential therapeutic targets |
Keating, Julie A.; Striker, Rob |
2011 |
2011-11-24 |
None |
N |
PMC3334462 |
22113983.0 |
10.1002/rmv.722 |
wz4nsbtc |
0.314069 |
|
|
| 21 |
Harrington_2010 |
Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics |
Harrington, K.J.; Vile, R.G.; Melcher, A.; Chester, J.; Pandha, H.S. |
2010 |
2010-06-30 |
None |
N |
PMC3915505 |
20223697.0 |
10.1016/j.cytogfr.2010.02.006 |
hcqe6xsr |
0.305991 |
|
Martínez_2008, Chen_2019 |
| 22 |
Li_S_2017 |
Interferon-omega: Current status in clinical applications |
Li, Shi-fang; Zhao, Fu-rong; Shao, Jun-jun; Xie, Yin-li; Chang, Hui-yun; Zhang, Yong-guang |
2017 |
2017-11-30 |
PMC |
N |
PMC7106160 |
28957693.0 |
10.1016/j.intimp.2017.08.028 |
b1e0bbrp |
0.301004 |
Jerome_2005 |
Doménech_2011 |